Vanguard Group Inc Ocuphire Pharma, Inc. Put Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding OCUP
# of Institutions
52Shares Held
3.42MCall Options Held
3.6KPut Options Held
6.2K-
Rice Hall James & Associates, LLC292KShares$452,5760.04% of portfolio
-
Geode Capital Management, LLC Boston, MA234KShares$363,3160.0% of portfolio
-
Richmond Brothers, Inc. Jackson, MI227KShares$352,5640.87% of portfolio
-
Mai Capital Management224KShares$347,1530.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX210KShares$325,4080.01% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $31.9M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...